Tidemark LLC Takes $338,000 Position in Johnson & Johnson (NYSE:JNJ)

Tidemark LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,158 shares of the company’s stock, valued at approximately $338,000.

A number of other hedge funds have also made changes to their positions in the stock. Sand Hill Global Advisors LLC boosted its stake in Johnson & Johnson by 0.7% during the 4th quarter. Sand Hill Global Advisors LLC now owns 58,702 shares of the company’s stock valued at $9,201,000 after purchasing an additional 405 shares during the period. Pzena Investment Management LLC boosted its stake in Johnson & Johnson by 0.6% during the 4th quarter. Pzena Investment Management LLC now owns 637,662 shares of the company’s stock valued at $99,947,000 after purchasing an additional 3,645 shares during the period. Central Valley Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $898,000. InterOcean Capital Group LLC lifted its position in shares of Johnson & Johnson by 4.3% in the 4th quarter. InterOcean Capital Group LLC now owns 272,240 shares of the company’s stock worth $42,671,000 after acquiring an additional 11,298 shares during the period. Finally, Abbot Financial Management Inc. lifted its position in shares of Johnson & Johnson by 1.5% in the 4th quarter. Abbot Financial Management Inc. now owns 17,570 shares of the company’s stock worth $2,754,000 after acquiring an additional 261 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Morgan Stanley reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, May 6th. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

View Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Price Performance

JNJ stock traded down $1.21 during midday trading on Friday, reaching $148.49. 1,519,876 shares of the company’s stock traded hands, compared to its average volume of 7,301,688. The company has a 50-day simple moving average of $151.53 and a two-hundred day simple moving average of $155.07. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a market cap of $357.37 billion, a price-to-earnings ratio of 9.26, a PEG ratio of 2.55 and a beta of 0.55. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.68 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.64 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.